GlassScriptPhysician profile
Uzma Iqbal
NPI 1154488195
$785.79
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $202 · 2021: $78.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $219.18 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $156.96 | 2019-2020 | |
| Genentech USA, INC. | $56.36 | 2019 | |
| Merck Sharp & Dohme LLC | $46.01 | 2019 | |
| Octapharma USA, INC. | $38.95 | 2019 | |
| Dova Pharmaceuticals | $33.58 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.90 | 2021 | |
| Seagen INC. | $24.78 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.35 | 2019 | |
| Daiichi Sankyo INC. | $22.18 | 2019 | |
| Janssen Biotech, INC. | $21.11 | 2020 | |
| Eisai INC. | $21.01 | 2020 | |
| Eagle Pharmaceuticals, INC. | $19.47 | 2020 | |
| Genzyme Corporation | $19.20 | 2019 | |
| Emd Serono, INC. | $18.53 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.65 | 2019 | |
| Pfizer INC. | $12.65 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.